Mitsubishi UFJ Trust & Banking Corp Sells 22,810 Shares of DexCom, Inc. (NASDAQ:DXCM)

Mitsubishi UFJ Trust & Banking Corp reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 3.6% during the fourth quarter, HoldingsChannel reports. The firm owned 606,716 shares of the medical device company’s stock after selling 22,810 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in DexCom were worth $47,184,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc bought a new stake in shares of DexCom during the 4th quarter worth $25,000. Private Trust Co. NA raised its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC bought a new position in shares of DexCom during the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 2.3 %

Shares of DXCM opened at $73.55 on Wednesday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The firm’s 50-day moving average price is $83.13 and its 200-day moving average price is $77.11. The firm has a market capitalization of $28.74 billion, a price-to-earnings ratio of 51.43, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on DXCM shares. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Cfra Research upgraded shares of DexCom to a “hold” rating in a research report on Friday, March 21st. Finally, Wells Fargo & Company restated an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average target price of $99.82.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 33,359 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock valued at $8,044,178 over the last ninety days. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.